Medivolve Inc. (MEDVF)
USD 0.01
(133.33%)
USD 0.01
(133.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.97 Million CAD | -194.12% |
| 2022 | -11.56 Million CAD | -105.46% |
| 2021 | 18.53 Million CAD | 189.35% |
| 2020 | -19.01 Million CAD | -698.46% |
| 2019 | -2.38 Million CAD | -85.08% |
| 2018 | -920.84 Thousand CAD | 88.46% |
| 2017 | -3.92 Million CAD | -724.87% |
| 2016 | -819.51 Thousand CAD | -60.57% |
| 2015 | -842.02 Thousand CAD | 54.29% |
| 2014 | -1.84 Million CAD | -16.26% |
| 2013 | -1.85 Million CAD | -3880.7% |
| 2012 | -1.58 Million CAD | 98.09% |
| 2011 | -2.07 Million CAD | -0.03% |
| 2010 | -2.03 Million CAD | -15.95% |
| 2009 | -1.79 Million CAD | -40.88% |
| 2008 | -1.27 Million CAD | -817.47% |
| 2007 | -138.69 Thousand CAD | -3.14% |
| 2006 | -134.47 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -416.27 Thousand CAD | -140.72% |
| 2023 Q3 | -1.1 Million CAD | 48.97% |
| 2023 FY | - CAD | -194.12% |
| 2023 Q4 | -249.98 Thousand CAD | 77.39% |
| 2023 Q1 | -2.17 Million CAD | -116.52% |
| 2023 Q2 | -2.16 Million CAD | 0.54% |
| 2022 Q4 | 13.19 Million CAD | 423.76% |
| 2022 Q3 | -4.07 Million CAD | 16.21% |
| 2022 Q2 | -4.86 Million CAD | -214.15% |
| 2022 FY | - CAD | -105.46% |
| 2022 Q1 | -1.54 Million CAD | -108.13% |
| 2021 FY | - CAD | 189.35% |
| 2021 Q1 | -5.88 Million CAD | 49.28% |
| 2021 Q2 | -3.01 Million CAD | 48.73% |
| 2021 Q3 | 7.04 Million CAD | 333.46% |
| 2021 Q4 | 19.04 Million CAD | 170.19% |
| 2020 Q4 | -11.6 Million CAD | -402.41% |
| 2020 FY | - CAD | -698.46% |
| 2020 Q1 | -1 Million CAD | -0.29% |
| 2020 Q2 | -6.95 Million CAD | -595.49% |
| 2020 Q3 | -2.31 Million CAD | 66.8% |
| 2019 Q3 | -306.95 Thousand CAD | 62.4% |
| 2019 FY | - CAD | -85.08% |
| 2019 Q1 | -260.72 Thousand CAD | 49.83% |
| 2019 Q2 | -816.43 Thousand CAD | -213.13% |
| 2019 Q4 | -997.83 Thousand CAD | -225.07% |
| 2018 Q4 | -519.69 Thousand CAD | -182.44% |
| 2018 Q3 | -184 Thousand CAD | 28.14% |
| 2018 Q2 | -256.05 Thousand CAD | 21.75% |
| 2018 FY | - CAD | 88.46% |
| 2018 Q1 | -327.22 Thousand CAD | 96.76% |
| 2017 Q4 | -10.08 Million CAD | -2283.5% |
| 2017 FY | - CAD | -724.87% |
| 2017 Q3 | -423.25 Thousand CAD | -59.5% |
| 2017 Q2 | -265.37 Thousand CAD | 29.37% |
| 2017 Q1 | -375.71 Thousand CAD | 63.16% |
| 2016 Q3 | 74.67 Thousand CAD | 136.52% |
| 2016 Q2 | -204.49 Thousand CAD | -0.96% |
| 2016 Q1 | -202.54 Thousand CAD | -125.79% |
| 2016 FY | - CAD | -60.57% |
| 2016 Q4 | -1.01 Million CAD | -1465.69% |
| 2015 FY | - CAD | 54.29% |
| 2015 Q4 | -89.7 Thousand CAD | 58.39% |
| 2015 Q3 | -215.6 Thousand CAD | 16.37% |
| 2015 Q2 | -257.8 Thousand CAD | 7.57% |
| 2015 Q1 | -278.91 Thousand CAD | 45.92% |
| 2014 Q2 | -667.51 Thousand CAD | -71.76% |
| 2014 Q1 | -388.62 Thousand CAD | 7.78% |
| 2014 Q3 | -270.2 Thousand CAD | 59.52% |
| 2014 FY | - CAD | -16.26% |
| 2014 Q4 | -515.72 Thousand CAD | -90.86% |
| 2013 Q3 | -343.84 Thousand CAD | 11.1% |
| 2013 Q1 | 3.59 Million CAD | 187.79% |
| 2013 Q2 | -386.75 Thousand CAD | -110.75% |
| 2013 Q4 | -421.4 Thousand CAD | -22.56% |
| 2013 FY | - CAD | -3880.7% |
| 2012 FY | - CAD | 98.09% |
| 2012 Q4 | 1.25 Million CAD | 379.09% |
| 2012 Q3 | -447.9 Thousand CAD | -23.58% |
| 2012 Q2 | -362.44 Thousand CAD | 23.92% |
| 2012 Q1 | -476.41 Thousand CAD | -7.59% |
| 2011 Q3 | -248.09 Thousand CAD | 75.52% |
| 2011 Q1 | -374.85 Thousand CAD | 14.44% |
| 2011 FY | - CAD | -0.03% |
| 2011 Q2 | -1.01 Million CAD | -170.37% |
| 2011 Q4 | -442.8 Thousand CAD | -78.49% |
| 2010 Q4 | -438.14 Thousand CAD | -8.8% |
| 2010 Q3 | -402.7 Thousand CAD | 34.82% |
| 2010 Q2 | -617.82 Thousand CAD | 0.35% |
| 2010 FY | - CAD | -15.95% |
| 2010 Q1 | -619.97 Thousand CAD | -92.18% |
| 2009 Q2 | -291.98 Thousand CAD | 10.63% |
| 2009 FY | - CAD | -40.88% |
| 2009 Q3 | -870.71 Thousand CAD | -198.21% |
| 2009 Q1 | -326.71 Thousand CAD | -125.14% |
| 2009 Q4 | -322.59 Thousand CAD | 62.95% |
| 2008 Q1 | -53.48 Thousand CAD | 43.07% |
| 2008 Q4 | 1.29 Million CAD | 158.39% |
| 2008 Q3 | -2.22 Million CAD | -659.33% |
| 2008 FY | - CAD | -817.47% |
| 2008 Q2 | -293.08 Thousand CAD | -448.03% |
| 2007 Q1 | -5377.00 CAD | 24.95% |
| 2007 Q3 | -39.17 Thousand CAD | -18205.61% |
| 2007 Q4 | -93.93 Thousand CAD | -139.79% |
| 2007 Q2 | -214.00 CAD | 96.02% |
| 2007 FY | - CAD | -3.14% |
| 2006 FY | - CAD | 0.0% |
| 2006 Q2 | -54.84 Thousand CAD | -29.41% |
| 2006 Q4 | -7165.00 CAD | 76.18% |
| 2006 Q1 | -42.38 Thousand CAD | 0.0% |
| 2006 Q3 | -30.08 Thousand CAD | 45.16% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | -155.619% |
| Arrayit Corporation | -3.07 Million USD | 3.4% |
| Atlantic International Corp. | -5.38 Million USD | 44.841% |
| Biocept, Inc. | -30.24 Million USD | 90.169% |
| Bioqual, Inc. | 3.03 Million USD | 198.041% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | -292.52% |
| DermTech, Inc. | -97.89 Million USD | 96.963% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.102% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 85.314% |
| iMD Companies, Inc. | -154.65 Thousand USD | -1822.197% |
| IDenta Corp. | 71.58 Thousand USD | 4252.781% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 177.479% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 7783.771% |
| InVitro International | 6680.00 USD | 44603.757% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 45.312% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | -24400.173% |
| Medical Imaging Corp. | -896.74 Thousand USD | -231.517% |
| NovelStem International Corp. | -3.78 Million USD | 21.474% |
| Optigenex Inc. | -1.18 Million USD | -150.509% |
| PharmChem, Inc. | 1.05 Million USD | 382.105% |
| Proteome Sciences plc | -1.13 Million USD | -161.464% |
| Response Genetics, Inc | -19.66 Million USD | 84.883% |
| Rennova Health, Inc. | -234.81 Thousand USD | -1166.04% |
| RushNet, Inc. | -614.85 Thousand USD | -383.507% |
| ScreenPro Security Inc. | -3.43 Million USD | 13.451% |
| Stella Diagnostics Inc. | -5.7 Million USD | 47.913% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 71.053% |
| Todos Medical Ltd. | -9.39 Million USD | 68.354% |